Wehrli, M; Oppliger Leibundgut, E; Gattiker, H H; Manz, Markus G; Müller, A M; Goede, J S (2017). Response to tyrosine kinase hnhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1 rearrangement. The Oncologist, 22(4):480-483.
Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.